Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.10
- Piotroski Score 2.00
- Grade Buy
- Symbol (CELC)
- Company Celcuity Inc.
- Price $12.74
- Changes Percentage (-0.31%)
- Change -$0.04
- Day Low $12.52
- Day High $12.99
- Year High $22.19
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $31.50
- High Stock Price Target $39.00
- Low Stock Price Target $24.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.78
- Trailing P/E Ratio -5.14
- Forward P/E Ratio -5.14
- P/E Growth -5.14
- Net Income $-63,779,116
Income Statement
Quarterly
Annual
Latest News of CELC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Celcuity Inc (CELC) Q3 2024 Earnings Call Highlights: Clinical Milestones and Financial Challenges
The CEO discussed the event rate and timeline shift in the earnings call. The event rate is influenced by patient responses to therapies, affecting the timeline. Roche's new therapy approval won't imp...
By Yahoo! Finance | 6 days ago -
Celcomdigi Berhad Second Quarter 2024 Earnings: EPS: RM0.035 (vs RM0.029 in 2Q 2023)
Celcomdigi Berhad's revenue remained flat at RM3.12b, with net income up 18% to RM406.0m. Profit margin increased to 13%, and EPS rose to RM0.035. Future revenue growth is forecasted at 2....
By Yahoo! Finance | 3 months ago
